Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Agomelatine versus escitalopram for depression in patients with epilepsy
2017-000990-35Phase 4Completed
- Sponsor
- University of Rome Tor Vergata, Department of Systems Medicine
- Start
- Jan 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in major depressive disorder (MDD) and epilepsy comparing Agomelatine with Escitalopram active control (2 arms). Primary endpoint: Efficacy. Started Jan 2020; status: completed.
02
Drugs
agomelatineescitalopram
03
Conditions
major depressive disorder (MDD)epilepsy
Beyond the preview
Go deeper on 2017-000990-35.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-000990-35.